Now online Clinical Cancer Research- Phase IB study ipatasertib plus ipatasertib in mCR prostate cancer post-NHA. No evidence of synergistic or additive antitumor activity. No clear signal of benefit in biomarker +ve populations either.
My take: Still no role for targeting PI3K pathway in mCRPC
Source: Arun Azad/Twitter